Starpharma Holdings Limited signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), to fund a clinical trial to test the use of VivaGel; in the prevention of genital herpes. Genital herpes is the second indication for which VivaGel; is being developed.
For details visit,
formatting link